ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Kangstem Biotech (217730.KQ)
Kangstem Biotech stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · KOSDAQ · South Korea
₩1,865▼ -0.96%
Prices as of Oct 27, 2026 · KRW
Chance of rising in 1 month
46%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Kangstem Biotech in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Kangstem Biotech
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Kangstem Biotech a 46% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between ₩1,619 and ₩2,080; in 9 out of 10, between ₩1,297 and ₩2,597. Estimated annual volatility is 71%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- ₩170B
- Market cap (USD)
- $128M
- 52-week high
- ₩4,690
- 52-week low
- ₩1,376
- Revenue (12 months)
- ₩3.0B
- Gross margin
- 13.6%
- Net margin
- 0.0%
- Beta
- 0.40
What this means
ATLAS does not publish a fair value for 217730.KQ right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks 217730.KQ has traded between ₩1,376 and ₩4,690. Today it is 60.2% below that high and 36% above its low.
Its beta is 0.40: it tends to move less than the market.
About the company
Kangstem Biotech Co., Ltd. a biopharmaceutical company, develops stem cell therapeutic products for rare and incurable diseases.
Want to see everything about Kangstem Biotech?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Kangstem Biotech do?
Kangstem Biotech Co., Ltd. a biopharmaceutical company, develops stem cell therapeutic products for rare and incurable diseases.
What is the chance 217730.KQ goes up next month?
46%: close to a coin flip. In half of the simulated outcomes, 217730.KQ ends the month between ₩1,619 and ₩2,080.
How big is Kangstem Biotech and what is its P/E ratio?
Kangstem Biotech's market capitalization is ₩170B. We do not show a P/E because it has no positive earnings to base one on.
How volatile is 217730.KQ?
ATLAS estimates annual volatility at 71%. In a typical month, half of the outcomes end between ₩1,619 and ₩2,080.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer